Steno Diabetes Center

Research facility


Location: Gentofte, Denmark (DK) DK

ISNI: 0000000406467285

ROR: https://ror.org/03w7awk87

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (2024) Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JF, Bakris G, Baeres FM, et al. Journal article From Global Domains to Physical Activity Environments: Development and Initial Validation of a Questionnaire-Based Physical Literacy Measure Designed for Large-Scale Population Surveys (2024) Elsborg P, Melby PS, Kurtzhals M, Kirkegaard H, Carl J, Rask S, Bentsen P, NIelsen G Journal article Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial (2024) Mann JF, Rossing P, Bakris G, Belmar N, Bosch-Traberg H, Busch R, Charytan DM, et al. Journal article Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes (2023) Agarwal R, Ruilope LM, Ruiz-Hurtado G, Haller H, Schmieder R, Anker SD, Filippatos G, et al. Journal article Blood pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes (2022) Ruilope LM, Agarwal R, Anker SD, Filippatos G, Pitt B, Rossing P, Sarafidis P, et al. Journal article Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE) (2022) Green JB, Mottl AK, Bakris G, Heerspink HJL, Mann JFE, Mcgill JB, Nangaku M, et al. Journal article Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial (2022) Waijer SW, Vart P, Cherney DZ, Chertow GM, Jongs N, Langkilde AM, Mann JFE, et al. Journal article Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER (2022) Shaman AM, Bain SC, Bakris GL, Buse JB, Idorn T, Mahaffey KW, Mann JF, et al. Journal article Genetic loci and prioritization of genes for kidney function decline derived from a meta-analysis of 62 longitudinal genome-wide association studies (2022) Gorski M, Rasheed H, Teumer A, Thomas LF, Graham SE, Sveinbjornsson G, Winkler TW, et al. Journal article Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis (2021) Mann J, Buse JB, Idorn T, Leiter LA, Pratley RE, Rasmussen S, Vilsboll T, et al. Journal article
1 2 3